|Over a month ago|
Venus Concept files to sell 15.58M shares of common stock for holders 16:4304/1704/17/20
Venus Concept 510(k) premarket notification posted by FDA » 11:1904/0604/06/20
The FDA issued a…
The FDA issued a "Substantially Equivalent" decision on April 1 for the Venus Viva system based on the application made by Venus Concept USA, according to a 510(k) Premarket Notification posted to the FDA website. Reference Link
Fly Intel: Top five analyst downgrades » 10:1003/3103/31/20
AMRN, HEXO, BKR, VERO, CRON
downgraded Cronos Group…
downgraded Cronos Group Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amarin (AMRN) downgraded to Hold from Buy at Jefferies with analyst Michael Yee expecting the stock to be range-bound until there is more clarity on an appeal to last night's negative patent decision and scenarios where generics may not immediately hit. 2. Hexo (HEXO) downgraded to Hold from Buy at Desjardins with analyst John Chu saying near-term funding requirements overshadow better than expected Q2 adjusted EBITDA loss as the company will need up to C$55M in equity financing by April 30. 3. Baker Hughes (BKR) downgraded to Hold from Buy at Argus withanalyst Bill Selesky warning that dramatically lower crude oil prices and demand impact of COVID-19 will lead to greater oil supply imbalances and a sharp deceleration in drilling activity starting in Q2. 4. Venus Concept (VERO) downgraded to Perform from Outperform at Oppenheimer as COVID-19 clouds outlook with analyst Suraj Kalia noting that the COVID-19 situation has forced the company to pull fiscal year 2020 guidance, therefore leaving a level of uncertainty in numbers. 5. Cronos Group (CRON) downgraded to Sell from Hold at Canaccord with analyst sayinh Q4 results came in below expectations on a modest top-line improvement, inventory write-offs, and deepening adjusted EBITDA losses. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook » 08:0303/3103/31/20
As previously reported,…
As previously reported, Oppenheimer analyst Suraj Kalia downgraded Venus Concept to Perform from Outperform. The analyst notes that the COVID-19 situation has forced the company to pull fiscal year 2020 guidance, therefore leaving a level of uncertainty in numbers. While Kalia believes in this CEO and business model, the current uncertainty in outlook forces the analyst to tactically move to the sidelines and wait till the environment stabilizes.
Venus Concept downgraded to Perform from Outperform at Oppenheimer » 06:5103/3103/31/20
Oppenheimer analyst Suraj…
Oppenheimer analyst Suraj Kalia downgraded Venus Concept to Perform from Outperform.
Venus Concept reports Q4 EPS ($1.07), consensus (41c) » 16:1203/3003/30/20
Reports Q4 revenue…
Reports Q4 revenue $31.9M, consensus $32.71M. "2019 was a year of significant advancement and change for Venus Concept," said Domenic Serafino, Chief Executive Officer of Venus Concept. "We delivered solid commercial execution, received new regulatory clearances and launched two new products in the U.S., and a total of four in international markets; we closed our merger transaction on November 7, 2019 and we made significant progress in enhancing our financial condition with multiple financing transactions. The integration of our two companies is progressing rapidly and we remain excited by the long-term prospects of both the combined global commercial team, and the potentially powerful combination of Venus' expertise in non-invasive energy-based technologies for aesthetic applications and Restoration Robotics' expertise in robotic technology, 3D pre-operative planning and software. We ended the year by delivering fourth quarter revenue, giving effect to the merger for the full year, at the high-end of our preliminary range, driven by 2% growth in the legacy Venus Concept business, which offset the expected softer sales performance in the former Restoration Robotics business compared to the prior year."
|Over a quarter ago|
Venus Concept appoints Chad Zaring as CCO » 07:5003/0303/03/20
Venus Concept (VERO)…
Venus Concept (VERO) announced that it has expanded its Executive Team with the appointment of Chad Zaring to the newly-created role of Chief Commercial Officer, effective February 10, 2020. Prior to joining the Venus Concept, Mr. Zaring served as the Chief Commercial Officer at Titan Medical (TMDI).
Venus Concept receives NeoGraft license, CE Mark approval to market Venus Bliss » 16:0902/1402/14/20
Venus Concept announced…
Venus Concept announced that it has received CE Mark approval to market Venus Bliss for non-invasive lipolysis of the abdomen and flanks, skin tightening, circumferential reduction and cellulite reduction and a medical device license issued by Health Canada to market NeoGraft 2.0 for hair restoration. Venus Bliss is a non-invasive medical aesthetic device that offers a comprehensive solution to fat reduction and cellulite reduction with two technologies in one system. The system uses the company's proprietary technology which combines multi-polar radio frequency and pulsed electro magnetic fields with advanced VariPulse technology. The Venus Bliss treats focal fat in the abdomen and flanks through non-invasive lipolysis, resulting in circumferential reduction. The Venus Bliss treatment leverages the applicator technology to tighten lax skin and to reduce the appearance of cellulite.
Venus Concept files to sell 16.39M shares of common stock for holders 17:0601/3101/31/20
Fly Intel: After Hours Movers » 18:2601/0901/09/20
SNX, ACRS, MRNA, RARE, VERO, ISRG, KBH, PTLA, SPWH, URBN, GRUB
UP AFTER EARNINGS: Synnex…
UP AFTER EARNINGS: Synnex (SNX), up 7.9%. ALSO HIGHER: Aclaris Therapeutics (ACRS), up 24.2% after announcing "positive" results from its Phase 1 trial of ATI-450... Moderna (MRNA), up 20.4% after reporting "positive" safety and immunogenicity Phase 1 data from its CMV vaccine study... Ultragenyx (RARE), up 17.9% after reporting data on Cohort 3 and 2 from study of DTX301... Venus Concept (VERO), up 6% after Oppenheimer initiated coverage on the stock with an Outperform rating... Intuitive Surgical (ISRG), up 2.3% after reporting preliminary Q4 revenue above estimates. DOWN AFTER EARNINGS: KB Home (KBH), down 2%. ALSO LOWER: Portola Pharmaceuticals (PTLA), down 39.4% after announcing preliminary Andexx net revenues for Q4... Sportsman's Warehouse (SPWH), down 16% after providing guidance for Q4 and fiscal 2019... Urban Outfitters (URBN), down 9.7% after reporting holiday sales... GrubHub (GRUB), down 7.8% after Bloomberg said the company isn't running a sale process.